ClinicalTrials.Veeva

Menu
P

Pinnacle Research Group | Anniston, AL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Methotrexate
AC2993
Canakinumab
ASN002
Glucose
Vonoprazan
BI 695501
Lansoprazole
Xyrem®
PE0139

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 127 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active pso...

Active, not recruiting
Psoriatic Arthritis
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Placebo
Biological: Risankizumab

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Active, not recruiting
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage...

Enrolling
Systemic Lupus Erythematosus
Drug: DS-7011a
Drug: Placebo
Locations recently updated

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Deucravacitinib
Locations recently updated

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo
Locations recently updated

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo
Locations recently updated

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Enrolling
Obesity
Drug: Matching Placebo-Garetosmab
Drug: Garetosmab

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV...

Enrolling
Clostridium Difficile (C. Difficile)
Drug: DNV3837

This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which c...

Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Device: Active Stimulation

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Placebo
Drug: Obicetrapib

A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and...

Active, not recruiting
Overweight or Obesity
Obese
Drug: Semaglutide
Biological: Bimagrumab

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenz...

Active, not recruiting
Seasonal Influenza
Biological: Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Biological: mRNA-1010

Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relati...

Enrolling
Endometriosis
Drug: Elagolix
Drug: Placebo

This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part...

Active, not recruiting
Celiac Disease
Drug: Placebo
Drug: DONQ52

Trial sponsors

Pfizer logo
Lilly logo
AstraZeneca logo
Boehringer Ingelheim logo
Novartis logo
AbbVie logo
Astellas logo
Amgen logo
A
MedImmune logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems